MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma? (Review)

Ma,Ruixia; Zhao,Maomao; Zou,Xin; Zhou,Jianye; Bai,Zhongtian

doi:10.3892/ol.2021.12586

MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma? (Review)

Authors:
- Ruixia Ma
- Maomao Zhao
- Xin Zou
- Jianye Zhou
- Zhongtian Bai
View Affiliations

Affiliations: The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Key Laboratory of Stomatology of State Ethnic Affairs Commission, Northwest Minzu University, Lanzhou, Gansu 730000, P.R. China
Published online on: February 24, 2021 https://doi.org/10.3892/ol.2021.12586
Article Number: 324

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a life‑threatening cancer of the digestive system, with complex pathogenesis affected by a broad spectrum of genetic and epigenetic factors. Among several factors, microRNAs (miRNAs), which are considered regulators of the post‑transcriptional gene expression, play important roles in determining the malignant phenotype of HCC. In recent years, the advances in molecular genetics have resulted in the characterization of complex genetic factors and in the identification of epigenetic mechanisms of diseases. Accumulating data have suggested that miRNA polymorphisms are involved in tumorigenesis and prognosis, suggesting that the miRNAs may serve as a target for HCC with regard to pathogenesis and prognosis. In the present review, a comprehensive and detailed literature search was conducted and the role of miRNA polymorphisms in the pathogenesis and prognosis of HCC is summarized. The data proposed the use of miRNAs as targets for the diagnosis and treatment of HCC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	European Association for the Study of the Liver, . EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
3	Zhou F, Shang W, Yu X and Tian J: Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 38:741–767. 2018. View Article : Google Scholar : PubMed/NCBI
4	Harding JJ, Khalil DN and Abou-Alfa GK: Biomarkers: What role do they play (If Any) for diagnosis, prognosis and tumor response prediction for hepatocellular carcinoma? Dig Dis Sci. 64:918–927. 2019. View Article : Google Scholar : PubMed/NCBI
5	Wang Y and Wan YY: Golgi protein 73, hepatocellular carcinoma and other types of cancers. Liver Res. 4:161–167. 2020. View Article : Google Scholar : PubMed/NCBI
6	Wang X, Zhang Y, Yang N, He H, Tao X, Kou C and Jiang J: Evaluation of the combined application of AFP, AFP-L3%, and DCP for hepatocellular carcinoma diagnosis: A Meta-analysis. Biomed Res Int. 2020:50876432020.PubMed/NCBI
7	Zhu M, Zheng J, Wu F, Kang B, Liang J, Heskia F, Zhang X and Shan Y: OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. J Med Virol. Feb 11–2021.(Epub ahead of print). doi: 10.1002/jmv.25704.
8	Yan Z, Zhou Z, Li C, Yang X, Yang L, Dai S, Zhao J, Ni H, Li S and Yao Y: Polymorphisms in miRNA genes play roles in the initiation and development of cervical cancer. J Cancer. 10:4747–4753. 2019. View Article : Google Scholar : PubMed/NCBI
9	Ryan BM: microRNAs in cancer susceptibility. Adv Cancer Res. 135:151–171. 2017. View Article : Google Scholar : PubMed/NCBI
10	Zóia MA, Azevedo FV, Vecchi L, Mota ST, Rodovalho VR, Cordeiro AO, Correia LI, Silva AC, Ávila VM, Araújo TG and Goulart LR: Inhibition of triple-negative breast cancer cell aggressiveness by cathepsin D blockage: Role of Annexin A1. Int J Mol Sci. 20:13372019. View Article : Google Scholar
11	Farokhizadeh Z, Dehbidi S, Geramizadeh B, Yaghobi R, Malekhosseini SA, Behmanesh M, Sanati MH, Afshari A, Moravej A and Karimi MH: Association of MicroRNA polymorphisms with hepatocellular carcinoma in an iranian population. Ann Lab Med. 39:58–66. 2019. View Article : Google Scholar : PubMed/NCBI
12	Akkız H, Bayram S, Bekar A, Akgöllü E and Ulger Y: A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: A case-control study. J Viral Hepat. 18:e399–e407. 2011. View Article : Google Scholar : PubMed/NCBI
13	Tian T, Wang M, Zhu W, Dai ZM, Lin S, Yang PT, Liu XH, Liu K, Zhu YY, Zheng Y, et al: MiR-146a and miR-196a-2 polymorphisms are associated with hepatitis virus-related hepatocellular cancer risk: A meta-analysis. Aging (Albany NY). 9:381–392. 2017. View Article : Google Scholar : PubMed/NCBI
14	Han Y, Pu R, Han X, Zhao J, Zhang Y, Zhang Q, Yin J, Xie J, Shen Q, Deng Y, et al: Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One. 8:e585642013. View Article : Google Scholar : PubMed/NCBI
15	Kim HY, Yoon JH, Lee HS, Cheong JY, Cho SW, Shin HD and Kim YJ: MicroRNA-196A-2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. J Med Virol. 86:446–453. 2014. View Article : Google Scholar : PubMed/NCBI
16	Li XD, Li ZG, Song XX and Liu CF: A variant in microRNA-196a2 is associated with susceptibility to hepatocellular carcinoma in Chinese patients with cirrhosis. Pathology. 42:669–673. 2010. View Article : Google Scholar : PubMed/NCBI
17	Riazalhosseini B, Mohamed Z, Apalasamy YD, Eng HS and Mohamed R: Association between microRNA-196A2 and microRNA-146A polymorphisms and progression to cirrhosis and hepatocellular carcinoma in patients with viral hepatitis B. Pharmacogenet Genomics. 26:74–79. 2016. View Article : Google Scholar : PubMed/NCBI
18	Kou JT, Fan H, Han D, Li L, Li P, Zhu J, Ma J, Zhang ZH and He Q: Association between four common microRNA polymorphisms and the risk of hepatocellular carcinoma and HBV infection. Oncol Lett. 8:1255–1260. 2014. View Article : Google Scholar : PubMed/NCBI
19	Kang Z, Li Y, He X, Jiu T, Wei J, Tian F and Gu C: Quantitative assessment of the association between miR-196a2 rs11614913 polymorphism and cancer risk: Evidence based on 45,816 subjects. Tumour Biol. 35:6271–6282. 2014. View Article : Google Scholar : PubMed/NCBI
20	Yu JY, Hu F, Du W, Ma XL and Yuan K: Study of the association between five polymorphisms and risk of hepatocellular carcinoma: A meta-analysis. J Chin Med Assoc. 80:191–203. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zheng L, Zhuang C, Zhao J and Ming L: Functional miR-146a, miR-149, miR-196a2 and miR-499 polymorphisms and the susceptibility to hepatocellular carcinoma: An updated meta-analysis. Clin Res Hepatol Gastroenterol. 41:664–676. 2017. View Article : Google Scholar : PubMed/NCBI
22	Qi JH, Wang J, Chen J, Shen F, Huang JT, Sen S, Zhou X and Liu SM: High-resolution melting analysis reveals genetic polymorphisms in microRNAs confer hepatocellular carcinoma risk in Chinese patients. BMC Cancer. 14:6432014. View Article : Google Scholar : PubMed/NCBI
23	Qiu GP and Liu J: MicroRNA gene polymorphisms in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for primary hepatocellular carcinoma. Genet Test Mol Biomarkers. 205:579–586. 2016. View Article : Google Scholar
24	Xu X, Ling Q, Wang J, Xie H, Wei X, Lu D, Hu Q, Zhang X, Wu L, Zhou L and Zheng S: Donor miR-196a-2 polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation in a Han Chinese population. Int J Cancer. 138:620–629. 2016. View Article : Google Scholar : PubMed/NCBI
25	Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 27:5643–5647. 2008. View Article : Google Scholar : PubMed/NCBI
26	Wang Z, Zhang L, Shi X, Xu H, Wang T and Bian J: Association between two common polymorphisms and risk of hepatocellular carcinoma: Evidence from an updated meta-analysis. Biomed Res Int. 2014:4686052014.PubMed/NCBI
27	Wang BS, Liu Z, Xu WX and Sun SL: Functional polymorphisms in microRNAs and susceptibility to liver cancer: A meta-analysis and meta-regression. Genet Mol Res. 13:5426–5440. 2014. View Article : Google Scholar : PubMed/NCBI
28	Hu M, Zhao L, Hu S and Yang J: The association between two common polymorphisms in MicroRNAs and hepatocellular carcinoma risk in Asian population. PLoS One. 8:e570122013. View Article : Google Scholar : PubMed/NCBI
29	Wei W, Hu Z, Fu H, Tie Y, Zhang H, Wu Y and Zheng X: MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. Oncol Rep. 28:701–706. 2012. View Article : Google Scholar : PubMed/NCBI
30	Kim WH, Min KT, Jeon YJ, Kwon CI, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, Hwang SG, et al: Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene. 504:92–97. 2012. View Article : Google Scholar : PubMed/NCBI
31	Ma Y, Wang R, Zhang J, Li W, Gao C, Liu J and Wang J: Identification of miR-423 and miR-499 polymorphisms on affecting the risk of hepatocellular carcinoma in a large-scale population. Genet Test Mol Biomarkers. 18:516–524. 2014. View Article : Google Scholar : PubMed/NCBI
32	Luo G, Chao YL, Tang B, Li BS, Xiao YF, Xie R, Wang SM, Wu YY, Dong H, Liu XD, et al: miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F. Oncotarget. 6:37808–37823. 2015. View Article : Google Scholar : PubMed/NCBI
33	Wang R, Zhang J, Ma Y, Chen L, Guo S, Zhang X, Ma Y, Wu L, Pei X, Liu S, et al: Association study of miR-149 rs2292832 and miR-608 rs4919510 and the risk of hepatocellular carcinoma in a large-scale population. Mol Med Rep. 10:2736–2744. 2014. View Article : Google Scholar : PubMed/NCBI
34	Roy S, Levi E, Majumdar AP and Sarkar FH: Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 5:582012. View Article : Google Scholar : PubMed/NCBI
35	Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, et al: Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene. 524:156–160. 2013. View Article : Google Scholar : PubMed/NCBI
36	Liu CJ, Ma XW, Zhang XJ and Shen SQ: pri-miR-34b/c rs4938723 polymorphism is associated with hepatocellular carcinoma risk: A case-control study in a Chinese population. Int J Mol Epidemiol Genet. 8:1–7. 2017.PubMed/NCBI
37	Luna JM, Barajas JM, Teng KY, Sun HL, Moore MJ, Rice CM, Darnell RB and Ghoshal K: Argonaute CLIP defines a deregulated miR-122-bound transcriptome that correlates with patient survival in human liver cancer. Mol Cell. 67:400–410.e7. 2017. View Article : Google Scholar : PubMed/NCBI
38	Bei C, Liu S, Yu X, Qiu M, Tang B, Liao W, He S and Yu H: Single nucleotide polymorphisms in miR-122 are associated with the risk of hepatocellular carcinoma in a southern Chinese population. Biomed Res Int. 2018:15402012018. View Article : Google Scholar : PubMed/NCBI
39	Liu Y, Xie K, Wen J, Deng M, Li J and Hu Z: A genetic variant in microRNA-122 regulatory region confers risk for chronic hepatitis B virus infection and hepatocellular carcinoma in Han Chinese. J Med Virol. 86:1669–1674. 2014. View Article : Google Scholar : PubMed/NCBI
40	Wang T, Xu L, Jia R and Wei J: MiR-218 suppresses the metastasis and EMT of HCC cells via targeting SERBP1. Acta Biochim Biophys Sin (Shanghai). 49:383–391. 2017. View Article : Google Scholar : PubMed/NCBI
41	Han Y, Pu R, Han X, Zhao J, Li W, Yin J, Zhang Y, Shen Q, Xie J, Zhang Q, et al: Association of a potential functional pre-miR-218 polymorphism and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk. Liver Int. 34:728–736. 2014. View Article : Google Scholar : PubMed/NCBI
42	Zhang LS, Liang WB, Gao LB, Li HY, Li LJ, Chen PY, Liu Y, Chen TY, Han JG, Wei YG and Zhang L: Association between pri-miR-218 polymorphism and risk of hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol. 31:761–765. 2012. View Article : Google Scholar : PubMed/NCBI
43	Qi F, Huang M, Pan Y, Liu Y, Liu J, Wen J, Xie K, Shen H, Ma H, Miao Y and Hu Z: A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese. PLoS One. 9:e853942014. View Article : Google Scholar : PubMed/NCBI
44	Liu Y, Zhang Y, Wen J, Liu L, Zhai X, Liu J, Pan S, Chen J, Shen H and Hu Z: A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One. 7:e322302012. View Article : Google Scholar : PubMed/NCBI
45	An J, Liu J, Liu L, Liu Y, Pan Y, Huang M, Qi F, Wen J, Xie K, Ma H, et al: A genetic variant in primary miR-378 is associated with risk and prognosis of hepatocellular carcinoma in a Chinese population. PLoS One. 9:e937072014. View Article : Google Scholar : PubMed/NCBI
46	Cheong JY, Shin HD, Cho SW and Kim YJ: Association of polymorphism in microRNA 604 with susceptibility to persistent hepatitis B virus infection and development of hepatocellular carcinoma. J Korean Med Sci. 29:1523–1527. 2014. View Article : Google Scholar : PubMed/NCBI
47	Kwak MS, Lee DH, Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim CY, Cheong JY, et al: Association of polymorphism in pri-microRNAs-371-372-373 with the occurrence of hepatocellular carcinoma in hepatitis B virus infected patients. PLoS One. 7:e419832012. View Article : Google Scholar : PubMed/NCBI
48	Li W, Ma Y, Zeng D, Zhang J, Wang R, Hu J, Yang D, Hu H, Wang J and Liu J: Association between microRNA single nucleotide polymorphisms and the risk of hepatocellular carcinoma. Rev Med Chil. 144:508–515. 2016. View Article : Google Scholar : PubMed/NCBI
49	Min P, Li W, Zeng D, Ma Y, Xu D, Zheng W, Tang F, Chen J, Shi J, Hu H, et al: A single nucleotide variant in microRNA-1269a promotes the occurrence and process of hepatocellular carcinoma by targeting to oncogenes SPATS2L and LRP6. Bull Cancer. 104:311–320. 2017. View Article : Google Scholar : PubMed/NCBI
50	Wang Q, Yu X, Li Q, Qin L, Tan S, Zeng X, Qiu X, Tang B, Jin J, Liao W, et al: Association between miR-199a rs74723057 and MET rs1621 polymorphisms and the risk of hepatocellular carcinoma. Oncotarget. 7:79365–79371. 2016. View Article : Google Scholar : PubMed/NCBI
51	Wang C, Li L, Yin Z, Zhang Q, Zhao H, Tao R, Wang S, Hu S, He Y, Wang D, et al: An indel polymorphism within pre-miR3131 confers risk for hepatocellular carcinoma. Carcinogenesis. 38:168–176. 2017.PubMed/NCBI
52	He L, Meng D, Zhang SH, Zhang Y, Deng Z and Kong LB: microRNA-608 inhibits human hepatocellular carcinoma cell proliferation via targeting the BET family protein BRD4. Biochem Biophys Res Commun. 501:1060–1067. 2018. View Article : Google Scholar : PubMed/NCBI
53	Dai ZM, Lv JR, Liu K, Lei XM, Li W, Wu G, Liu XH, Zhu YX, Hao Q and Dai ZJ: The role of microRNA-608 polymorphism on the susceptibility and survival of cancer: A meta-analysis. Aging (Albany NY). 10:1402–1414. 2018. View Article : Google Scholar : PubMed/NCBI
54	Yu G, Xiao Q, Ma XP, Chen X, Shi Z, Zhang LY, Chen H, Zhang P, Ding DL, Huang HX, et al: miR-492G>C polymorphism (rs2289030) is associated with overall survival of hepatocellular carcinoma patients. Tumour Biol. 37:8961–8972. 2016. View Article : Google Scholar : PubMed/NCBI
55	Long XD, Huang XY, Yao JG, Liao P, Tang YJ, Ma Y and Xia Q: Polymorphisms in the precursor microRNAs and aflatoxin B1-related hepatocellular carcinoma. Mol Carcinog. 55:1060–1072. 2016. View Article : Google Scholar : PubMed/NCBI
56	Ji J, Xu M, Tu J, Zhao Z, Gao J, Chen M, Song J, Zhu H, Cheng X, Hui J, et al: MiR-155 and its functional variant rs767649 contribute to the susceptibility and survival of hepatocellular carcinoma. Oncotarget. 7:60303–60309. 2016. View Article : Google Scholar : PubMed/NCBI
57	Wei HX, Tian GX, Song JK, Yang LJ and Wang YP: The association between rs16917496 T/C polymorphism of SET8 gene and cancer risk in Asian populations: A meta-analysis. Biosci Rep. 38:BSR201807022018. View Article : Google Scholar : PubMed/NCBI